Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
July 22 2021 - 8:16AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of July 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
22 July 2021 07:00 BST
Non-Executive Board appointment
AstraZeneca PLC announced today that the Board has appointed
Andreas Rummelt as a Non-Executive Director, following the
completion yesterday of its acquisition of Alexion Pharmaceuticals,
Inc.
Dr. Rummelt has been a member of the Board of Alexion since 2010.
His effective date of appointment to AstraZeneca's Board is 1
August 2021, the same as that of AstraZeneca's new Executive
Director and Chief Financial Officer, Dr. Aradhana Sarin (formerly
Executive Vice-President, Chief Financial Officer of Alexion), as
previously announced on 4 June 2021.
Leif Johansson, Chairman of AstraZeneca said, "We are delighted to
welcome Andreas to AstraZeneca and look forward to working with
him. His extensive experience of the pharmaceutical industry and in
particular his technical R&D, manufacturing and quality
assurance expertise, together with his deep knowledge of Alexion,
will enable him to make a significant contribution to the Board's
work."
Biographical details - Andreas Rummelt
Dr. Andreas Rummelt has
more than 20 years' experience in executive management positions in
the pharmaceutical industry. His international career has focused
on technical research and development, manufacturing and quality,
as well as a period leading a generics business as Chief Executive
Officer. He is now Chairman and Managing Partner of InterPharmaLink
AG, a management consulting firm based in Basel,
Switzerland.
Dr. Rummelt was Group Head of Technical Operations and Quality at
Novartis and, from 2006 until 2010, served as a member of the
Executive Committee there. He originally joined Sandoz Pharma in
Basel, Switzerland in 1985 and held various positions of increasing
responsibility in Pharma Development, including Head of Worldwide
Technical Research and Development. From 1999, Dr. Rummelt
served as Global Head of Technical Operations and Quality of the
Pharmaceuticals Division of Novartis, and from 2004 to 2008, as
Global Chief Executive Officer of Sandoz, the Generics Division of
Novartis.
Dr. Rummelt has served as a Director of Alexion Pharmaceuticals,
Inc. since 2010 and is a member of the boards of various
privately-held biotech and pharmaceutical companies in Europe. He
is also member of the Scientific Advisory Committee of the Global
Antibiotic Research and Development Partnership based in Geneva,
Switzerland.
Dr. Rummelt is a pharmacist and earned his PhD in pharmaceutical
sciences from the University of Erlangen-Nuremberg, Germany. He
received his executive training in general management and
leadership from IMD in Lausanne, Switzerland; INSEAD in
Fontainebleau, France; and Harvard Business School in Cambridge, MA
in the US.
No disclosure obligations arise under paragraphs (1) to (6) of LR
9.6.13 R of the Financial Conduct Authority's Listing Rules in
respect of this appointment.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines in
Oncology, Rare Diseases and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries, and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
ENDS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
22 July
2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024